Cargando…

Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19

Multisystem inflammatory syndrome in children (MIS-C) has been widely reported in some children diagnosed with SARS-CoV-2. Clinical signs of MIS-C are manifested at 2 to 4 weeks after SARS-CoV-2 infection, where elevated biomarkers of inflammation and cardiac dysfunction are the hallmark of this syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada-Luna, Diego, Carreón-Torres, Elizabeth, González-Reyes, Susana, Martínez-Salazar, María Fernanda, Ortiz-Rodríguez, María Araceli, Ramírez-Moreno, Esther, Arias-Rico, José, Jiménez-Osorio, Angélica Saraí
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605437/
https://www.ncbi.nlm.nih.gov/pubmed/36295088
http://dx.doi.org/10.3390/life12101652
_version_ 1784818066449760256
author Estrada-Luna, Diego
Carreón-Torres, Elizabeth
González-Reyes, Susana
Martínez-Salazar, María Fernanda
Ortiz-Rodríguez, María Araceli
Ramírez-Moreno, Esther
Arias-Rico, José
Jiménez-Osorio, Angélica Saraí
author_facet Estrada-Luna, Diego
Carreón-Torres, Elizabeth
González-Reyes, Susana
Martínez-Salazar, María Fernanda
Ortiz-Rodríguez, María Araceli
Ramírez-Moreno, Esther
Arias-Rico, José
Jiménez-Osorio, Angélica Saraí
author_sort Estrada-Luna, Diego
collection PubMed
description Multisystem inflammatory syndrome in children (MIS-C) has been widely reported in some children diagnosed with SARS-CoV-2. Clinical signs of MIS-C are manifested at 2 to 4 weeks after SARS-CoV-2 infection, where elevated biomarkers of inflammation and cardiac dysfunction are the hallmark of this syndrome when infection or exposure to SARS-CoV-2 has been confirmed. However, after two years of acknowledgment, MIS-C treatment is still under research to reach safety and effectiveness in the acute phase in children. Therefore, in this review, we discuss the potential use of natural compounds with antioxidant and anti-inflammatory effects to reduce collateral damage caused by hyperinflammation in MIS-C pathology for new research in treatment and interventions.
format Online
Article
Text
id pubmed-9605437
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96054372022-10-27 Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19 Estrada-Luna, Diego Carreón-Torres, Elizabeth González-Reyes, Susana Martínez-Salazar, María Fernanda Ortiz-Rodríguez, María Araceli Ramírez-Moreno, Esther Arias-Rico, José Jiménez-Osorio, Angélica Saraí Life (Basel) Review Multisystem inflammatory syndrome in children (MIS-C) has been widely reported in some children diagnosed with SARS-CoV-2. Clinical signs of MIS-C are manifested at 2 to 4 weeks after SARS-CoV-2 infection, where elevated biomarkers of inflammation and cardiac dysfunction are the hallmark of this syndrome when infection or exposure to SARS-CoV-2 has been confirmed. However, after two years of acknowledgment, MIS-C treatment is still under research to reach safety and effectiveness in the acute phase in children. Therefore, in this review, we discuss the potential use of natural compounds with antioxidant and anti-inflammatory effects to reduce collateral damage caused by hyperinflammation in MIS-C pathology for new research in treatment and interventions. MDPI 2022-10-20 /pmc/articles/PMC9605437/ /pubmed/36295088 http://dx.doi.org/10.3390/life12101652 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Estrada-Luna, Diego
Carreón-Torres, Elizabeth
González-Reyes, Susana
Martínez-Salazar, María Fernanda
Ortiz-Rodríguez, María Araceli
Ramírez-Moreno, Esther
Arias-Rico, José
Jiménez-Osorio, Angélica Saraí
Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title_full Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title_fullStr Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title_full_unstemmed Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title_short Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19
title_sort nutraceuticals for complementary treatment of multisystem inflammatory syndrome in children: a perspective from their use in covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605437/
https://www.ncbi.nlm.nih.gov/pubmed/36295088
http://dx.doi.org/10.3390/life12101652
work_keys_str_mv AT estradalunadiego nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT carreontorreselizabeth nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT gonzalezreyessusana nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT martinezsalazarmariafernanda nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT ortizrodriguezmariaaraceli nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT ramirezmorenoesther nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT ariasricojose nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19
AT jimenezosorioangelicasarai nutraceuticalsforcomplementarytreatmentofmultisysteminflammatorysyndromeinchildrenaperspectivefromtheiruseincovid19